Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years.

Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years. Abstract Text:

Mark J Bolland,Andrew B Grey,Anne M Horne,Simon E Briggs,Mark G Thomas,Rod B Ellis-Pegler,Andrew F Woodhouse,Greg D Gamble,Ian R Reid,Mark J Bolland,Andrew B Grey,Anne M Horne,Simon E Briggs,Mark G Thomas,Rod B Ellis-Pegler,Andrew F Woodhouse,Greg D Gamble,Ian R Reid,

OBJECTIVE: Recently we reported that human immunodeficiency virus (HIV)-infected Caucasian men treated with highly active antiretroviral therapy (HAART) have normal weight-adjusted bone mineral density (BMD), in contrast to most other cross-sectional analyses, which have reported low BMD in HIV-infected patients. We have now addressed the question of whether there is accelerated BMD loss over time in HIV-infected men. DESIGN: A 2-year, prospective, longitudinal study. SUBJECTS: Twenty-three HAART-treated, HIV-infected men and 26 healthy controls. MEASUREMENTS: All participants had measurements of BMD and bone-related laboratory parameters at baseline, and a repeat measurement of BMD at 2 years. RESULTS: In the HIV-infected men the mean age was 47 years, the mean duration of infection was 8.2 years, and the mean duration of HAART was 54 months. Over 2 years of follow-up, BMD increased from baseline in the HIV-infected men by 2.6% at the lumbar spine (P = 0.05 vs. baseline), and remained stable at the total hip (mean change 0.1%, P > 0.99) and total body (mean change 0.6%, P = 0.39). Mean changes in BMD in the control group were 1.4% at the lumbar spine, -0.1% at the total hip, and -0.8% at the total body. The HIV-infected men lost less total body BMD than the control group (P = 0.01). In the HIV-infected men, body weight remained stable over 2 years while fat mass decreased and lean mass tended to increase, whereas in the controls, body weight and fat mass increased while lean mass remained stable. CONCLUSIONS: Accelerated bone loss does not occur in HIV-infected men treated with HAART. Monitoring of BMD in HIV-infected men may not be necessary.

Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years. Publishing Authors By Initials

MJ Bolland,AB Grey,AM Horne,SE Briggs,MG Thomas,RB Ellis-Pegler,AF Woodhouse,GD Gamble,IR Reid,MJ Bolland,AB Grey,AM Horne,SE Briggs,MG Thomas,RB Ellis-Pegler,AF Woodhouse,GD Gamble,IR Reid,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Clinical endocrinology

VOLUME: 67

Page Numbers: 270-5

Journal Abbreviation: Clin. Endocrinol. (Oxf)

ISSN: 0300-0664

DAY: 4

MONTH: 06

YEAR: 2007

Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 346653

Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years.

AFFILIATION: Department of Medicine, University of Auckland, Auckland, New Zealand. m.bolland@auckland.ac.nz

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Clin Endocrinol (Oxf)

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years Related Publications

• A review on the genetics of otosclerosis.
• Age-, gender-, and weight-related effects on levels of 25-hydroxyvitamin D are not mediated by vitamin D binding protein.
• Are exotic natural enemies an effective way of controlling invasive plants?
• Autofluorescence bronchoscopy for lung cancer surveillance based on risk assessment.
• Bisphosphonates.
• Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years.
• Co-regulation of the nitrogen-assimilatory gene cluster in Clostridium saccharobutylicum.
• Delayed Onset Muscle Soreness Following Inspiratory Threshold Loading In Healthy Men and Women: 681: May 31 9:30 AM - 9:45 AM.
• Demonstration of artificial visual percepts generated through thalamic microstimulation.
• Design of a 2 T multipole wiggler insertion device for the SRS.
• Digital three-dimensional modelling of the male pelvis and bicycle seats: impact of rider position and seat design on potential penile hypoxia and erectile dysfunction.
• Efficacy of murine monoclonal antibodies in RBC phenotyping of DAT-positive samples.
• Emerging methods in proteomics: top-down protein characterization by multistage tandem mass spectrometry.
• Femtosecond pump-probe studies of nitrosyl chloride photochemistry in solution.
• Genetic variability of Trypanosoma evansi isolates detected by inter-simple sequence repeat anchored-PCR and microsatellite.
• Globular clusters, hipparcos, and the age of the galaxy.
• Human hepatoblast phenotype maintained by hyaluronan hydrogels.
• Importance and the role of parents in specific learning disabilities.
• Inflammatory disease-induced muscle wasting: 105: 3:30 PM-4:00 PM.
• NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.
• Optical properties of micrometer size water droplets studied by cavity ringdown spectroscopy.
• Organisms associated with bacterial vaginosis in Nigerian women as determined by PCR-DGGE and 16S rRNA gene sequence.
• Oxidative stress, chronic disease, and muscle wasting.
• Patient-centered outcomes for frequent headaches.
• Prevention of experimental cancer and immunostimulation by vitamin E (immunosurveillance).
• Reasons for participation and non-participation in a randomized controlled trial: postal questionnaire surveys of women eligible for TOMBOLA (Trial Of Management of Borderline and Other Low-grade Abnormal smears).
• Sex after seventy: a pilot study of sexual function in older persons.
• The phenotypes of pluripotent human hepatic progenitors.
• The potential role of phosphodiesterase inhibitors in the management of asthma.
• Three new high-prevalence antigens in the Cromer blood group system.